Why Do Some Patients Respond to Cancer Treatment While Others Don't?
One of the reasons for this is genetic heterogeneity. Cancer cells can carry different mutations, even within the same tumour. These mutations influence how quickly a tumour grows and how sensitive it is to chemotherapy or radiation.
By : DC Correspondent
Update: 2026-11-21 17:16 GMT
When 45-year old Rajesh Mishra started experiencing a constant and painful swelling in his neck, a series of medical checkups revealed that he had stage IV lung cancer that had already spread to his lymph nodes and bones. He began his treatment right away. Six months later, his treatment had stopped responding and his cancer started progressing again.
In a different story, another patient, 45 years of age, diagnosed with Stage IV lung cancer, with a similar disease profile as Rajesh, showed positive response to the treatment and his condition slowly started to improve.
Both patients had the same type and stage of cancer, yet their responses to treatment were very different. This raises an important question: Why is it that some patients respond to cancer treatment and some don’t?
Dr VS Sai Sankalp Naidu, Oncologist, Assistant professor in MNJ Cancer Hospital, explains, “One thing we need to understand is that cancer is not a single disease. It can arise in different organs, and even when two patients have the same type and stage of cancer, the disease can behave very differently in each individual.”
One of the reasons for this is genetic heterogeneity. Cancer cells can carry different mutations, even within the same tumour. These mutations influence how quickly a tumour grows and how sensitive it is to chemotherapy or radiation.
“Apart from genetic heterogeneity, we also have something called the tumour microenvironment. Any tumour can have thousands of receptors on its surface, and these can behave differently in different individuals. For example, two people may have a common cold, but their recovery time can differ depending on their individual immunity. Similarly, the tumour microenvironment plays an important role in why patients respond differently to the same treatment.”, Dr Sankalp adds.
“Furthemore, even patients from different populations, such as Indian, African or European backgrounds, may have tumours with different genetic characteristics, which can influence their response to treatment. Understanding these genetic differences is therefore an important part of determining how a patient may respond to cancer treatment. This is where comprehensive genetic testing becomes relevant. By analysing the genetic mutations present in a tumour, these tests can help oncologists identify the molecular characteristics of the cancer and understand whether certain targeted therapies may be suitable for the patient instead of a standard one-size-fits all approach.”, adds Dr Sankalp.
In Rajesh's case, after initially undergoing chemotherapy, his tumour began growing again, indicating that the treatment was no longer working. His oncologists then recommended next-generation sequencing (NGS)-based comprehensive genomic profiling to understand the genetic changes driving his cancer.
A comprehensive genomic profiling test by 4baseCare, a precision oncology company that helps doctors make more informed treatment decisions by analysing the genetic profile of a patient's tumour, helped identify the genetic driver of Rajesh's cancer. This allowed his oncologists to consider a different targeted therapy.
Explaining the role of genomic testing in cancer treatment, Hitesh Goswami, CEO and Co-Founder of 4baseCare, says, "Advances in genomic medicine are helping us understand the genetic profile of a tumour and how it influences response to treatment. Genomic tests that use technologies like next-generation sequencing (NGS) allow us to look deeper into the biology of a cancer and identify specific genetic alterations that may help determine potential treatment options."
But what exactly is NGS and how does it help oncologists choose the right treatment?
Next-generation sequencing is a DNA sequencing technology that can analyse millions of DNA fragments at once. From genetic variations to changes in the tumour’s DNA, this technology allows oncologists to understand cancer in depth and help them assess whether certain targeted therapies may be more suitable for a patient.
Dr. VS Sai Sankalp Naidu, explains, "NGS testing helps us understand the genetic profile of a patient's cancer and identify which treatments may be more suitable for them. For instance, when a new patient comes to us, we generally start with first-line chemotherapy and assess the response over four to six cycles. While many patients respond, some may have stable disease, while others may experience disease progression. With genomic profiling, we can get additional information about the tumour's genetic characteristics and potential treatment sensitivities, rather than waiting to assess the response after several cycles of chemotherapy."
The answer to why some patients respond to cancer treatment while others don't lie in the differences in genetic makeup of their tumours. Two patients can have the same type and stage of cancer but their response to treatment can significantly vary. This is why cancer is moving away from a one-size-fits all approach to a much more personalized and targeted approach. Genomic testing can help oncologists look beyond conventional factors like size and stage and understand the biology of the tumour in detail. As cancer care moves towards a more personalised approach, understanding not just where the cancer originates, but what drives it, is becoming increasingly important.